MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include:
| (CAD) | Q1 2024 | % Change vs. Q1 2023 | Trailing Twelve Months (TTM) March 31, 2024 | % Change vs. TTM March 31, 2023 | ||
| Canadian Pharma Sales | 7,546,144 | 18 | % | 30,689,349 | 16 | % |
| International Pharma Sales | - | 0 | % | 1,047,747 | 789 | % |
| Total Company Sales | 7,733,636 | 19 | % | 32,841,244 | 20 | % |
| EBITDA1 | 2,204,193 | 45 | % | 8,614,037 | 28 | % |
| Net Income After Taxes (NIAT) | 1,768,727 | 50 | % | 7,053,608 | 40 | % |
| Fully Diluted EPS | 0.15 | 50 | % | 0.59 | 44 | % |
“Our Canadian pharmaceutical business got off to a fast start in Q1 2024 with 18% revenue growth over the comparative period,” said René Goehrum, President and CEO of BioSyent. “All of our Canadian pharmaceutical brands contributed to this growth during the quarter. Our three launch brands, FeraMAX® Pd Maintenance 45, Inofolic®, and Gelclair® also contributed modest incremental growth during Q1 2024. We remain focused on continuing to grow our Canadian pharmaceutical business during the remainder of the year with continued selling and promotional investment in our launch brands. I look forward to reporting on our progress in 2024.”
The CEO’s presentation on the Q1 2024 Results is available at the following link: www.biosyent.com/investors/
The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2024 and 2023 will be posted on www.sedarplus.ca on May 16, 2024.
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
As of the date of this press release, the Company has 11,585,169 common shares outstanding.
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Comprehensive Income | ||||||
| In Canadian Dollars | Q1 2024 | Q1 2023 | % Change | |||
| Net Revenues | 7,733,636 | 6,482,694 | 19% | |||
| Cost of Goods Sold | 1,589,762 | 1,147,962 | 38% | |||
| Gross Profit | 6,143,874 | 5,334,732 | 15% | |||
| Operating Expenses and Finance Income/Costs | 3,737,443 | 3,735,758 | 0% | |||
| Net Income Before Tax | 2,406,431 | 1,598,974 | 50% | |||
| Tax (including Deferred Tax) | 637,704 | 423,728 | 50% | |||
| Net Income After Taxes | 1,768,727 | 1,175,246 | 50% | |||
| Net Income After Taxes % to Net Revenues | 23% | 18% | ||||
| EBITDA | 2,204,193 | 1,516,634 | 45% | |||
| EBITDA % to Net Revenues | 29% | 23% | ||||
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Financial Position | ||||||
| AS AT | March 31, 2024 | December 31, 2023 | % Change | |||
| ASSETS | ||||||
| Cash, cash equivalents and short-term investments | $ | 23,687,796 | $ | 26,187,011 | -10 | % |
| Trade and other receivables | 2,791,794 | 3,477,096 | -20 | % | ||
| Inventory | 5,718,882 | 5,894,495 | -3 | % | ||
| Derivative asset | 11,550 | - | 100 | % | ||
| Prepaid expenses and deposits | 569,144 | 243,460 | 134 | % | ||
| Loans receivable - current | 73,452 | 69,419 | 6 | % | ||
| CURRENT ASSETS | 32,852,618 | 35,871,481 | -8 | % | ||
| Long term investments | 4,106,547 | 2,500,000 | 64 | % | ||
| Loans receivable - non current | 205,182 | 205,182 | 0 | % | ||
| Deferred tax asset | 343,607 | 359,470 | -4 | % | ||
| Property and equipment | 1,373,868 | 1,439,930 | -5 | % | ||
| Intangible assets | 1,114,612 | 1,152,876 | -3 | % | ||
| TOTAL NON CURRENT ASSETS | 7,143,816 | 5,657,458 | 26 | % | ||
| TOTAL ASSETS | $ | 39,996,434 | $ | 41,528,939 | -4 | % |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| CURRENT LIABILITIES | $ | 4,256,689 | $ | 5,533,850 | -23 | % |
| NON CURRENT LIABILITIES | 1,187,820 | 1,235,333 | -4 | % | ||
| Long term debt | - | - | 0 | % | ||
| Total Equity | 34,551,925 | 34,759,756 | -1 | % | ||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 39,996,434 | $ | 41,528,939 | -4 | % |
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 905-206-0013
Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
| Last Trade: | C$11.06 |
| Daily Change: | 0.05 0.45 |
| Daily Volume: | 1,501 |
| Market Cap: | C$128.190M |
September 20, 2024 August 26, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
